Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efruxifermin in NASH (BALANCED)
NCT03976401Phase 2Completed
- Sponsor
- Akero Therapeutics
- Start
- May 2019
- Primary completion
- Feb 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of efruxifermin in Nonalcoholic steatohepatitis (NASH), sponsored by Akero Therapeutics. Started May 2019; status: completed.
02
Drugs
efruxifermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03976401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976401.